Compare Regeneron Pharmaceuticals Inc (REGN) vs ProShares Ultra Semiconductors (USD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs ProShares Ultra Semiconductors — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while ProShares Ultra Semiconductors trades at $92.31. The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while ProShares Ultra Semiconductors pays none, and ProShares Ultra Semiconductors is trading nearer its 52-week high, Regeneron Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| REGN | USD | |
|---|---|---|
Market Cap | $70.79B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $812.27 | $113.53 |
52-Week Low | $545.46 | $39.58 |
Enterprise Value | $64.74B | — |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
USD stock trades at $83.24, up 1.19% with a bearish technical signal from moving averages. The company shows limited financial data availability, with key valuation and profitability ratios not provided. Recent corporate actions include a future dividend announcement for June 2026. Technical indicators show neutral oscillators but bearish momentum signals with support at $82 and resistance at $86.
The outlook remains cautious due to bearish technical indicators and incomplete fundamental data. Investment opportunities depend on forthcoming financial disclosures, while risks include market volatility and the stock's current technical weakness. The neutral sentiment from oscillators suggests potential stabilization near current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About ProShares Ultra Semiconductors
USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →
